UBS Group
IMNM icon

UBS Group’s Immunome IMNM Stock Holding History

UBS Group’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.47M Buy
432,912
+125,718
+41% +$2.8M ﹤0.01% 3419
2025
Q4 		$6.6M Sell
307,194
-276,748
-47% -$4.86M ﹤0.01% 3738
2025
Q3 		$6.84M Buy
583,942
+158,027
+37% +$1.57M ﹤0.01% 3705
2025
Q2 		$3.96M Buy
425,915
+81,864
+24% +$671K ﹤0.01% 4114
2025
Q1 		$2.32M Buy
344,051
+155,854
+83% +$1.5M ﹤0.01% 4586
2024
Q4 		$2M Buy
188,197
+108,957
+138% +$1.32M ﹤0.01% 4714
2024
Q3 		$1.16M Buy
79,240
+1,557
+2% +$22.1K ﹤0.01% 4525
2024
Q2 		$940K Buy
77,683
+53,032
+215% +$830K ﹤0.01% 4473
2024
Q1 		$608K Buy
+24,651
New +$500K ﹤0.01% 5034
2023
Q4 		– Sell
-14
Closed -$117 – 9583
2023
Q3 		$117 Sell
14
-1,044
-99% -$7.67K ﹤0.01% 8848
2023
Q2 		$8.37K Buy
1,058
+1,044
+7,457% +$5.71K ﹤0.01% 7244
2023
Q1 		$70 Sell
14
-460
-97% -$2.25K ﹤0.01% 9291
2022
Q4 		$1.05K Sell
474
-14,797
-97% -$59.6K ﹤0.01% 9973
2022
Q3 		$68K Buy
15,271
+13,943
+1,050% +$65.4K ﹤0.01% 6056
2022
Q2 		$4K Buy
1,328
+1,208
+1,007% +$4.39K ﹤0.01% 9076
2022
Q1 		$1K Sell
120
-2,371
-95% -$17.7K ﹤0.01% 9880
2021
Q4 		$32K Buy
2,491
+2,477
+17,693% +$44.2K ﹤0.01% 7327
2021
Q3 		$0 Sell
14
-1,356
-99% -$23.7K ﹤0.01% 9784
2021
Q2 		$24K Buy
1,370
+922
+206% +$20.4K ﹤0.01% 7142
2021
Q1 		$15K Sell
448
-586
-57% -$14.6K ﹤0.01% 7627
2020
Q4 		$10K Buy
+1,034
New +$12.1K ﹤0.01% 7486

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

UBS Group's IMNM Position: Q1 2026 in Review

UBS Group increased its Immunome (IMNM) stake by 41% in Q1 2026, buying an estimated $2.8M and bringing the position to 432,912 shares worth $9.47M. The position accounts for ﹤0.01% of the portfolio, ranked #3419.

UBS Group first reported a position in IMNM in Q4 2020 and has held it in 21 quarters since. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • UBS Group held 432,912 shares of Immunome worth $9.47M as of Q1 2026.
  • UBS Group bought 125,718 Immunome shares in Q1 2026, an estimated $2.8M.
  • Immunome made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #3419 holding.
  • UBS Group first reported a position in Immunome in Q4 2020 and has held it in 21 quarters since.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.